Abstract: Provided are a method for providing a personalized internet phone, and a terminal using the same.

Abstract: A carrier for delivering small interfering RNA (siRNA) into cells includes a cholesterol residue covalently bonded to oligoarginine. Mixing the siRNA with the carrier produces a complex-containing composition. Contacting a cell with the complex-containing composition results in delivery of the siRNA into the cell. Delivery of an siRNA targeted to vascular endothelial growth factor is a treatment for cancer. Methods of making the carrier and complex are also disclosed.

Abstract: Poly(disulfide amine)s, methods of making, and methods of use are described. Illustrative embodiments of the poly(disulfide amine)s include poly(N,N?-cystaminebisacrylamide-spermine), poly(N,N?-cystaminebisaciylamide-N,N?-bis(3-aminopropyl)1,3-propanediamine), poly(N,N?-cystaminebisacrylamide-N,N?-bis(3-amino-propyl)ethylenediamine), poly(N,N?-cystaminebisacrylamide-N,N?-bis(2-aminoethyl)-1,3-propanediamine), and poly(N,N?-cystaminebisacrylamide-triethylenetetramine). These compositions are made by Michael addition between N,N?-cystaminebisacrylamide and protected oligoamine monomers, followed by deprotection. Complexes are formed by mixing the poly(disulfide amine)s with a nucleic acid. Delivery of the nucleic acid into cells is carried out by contacting the cells with the nucleic acid/poly(disulfide amine) complexes.

Abstract: Plasmids useful for treating ischemic disease, such as ischemic heart disease, are described. The plasmids express vascular endothelial growth factor (VEGF) under the control of a promoter (RTP801) that is up-regulated under hypoxic conditions. Pharmaceutical compositions for treating ischemic disease include mixtures of the hypoxia-regulated VEGF plasmids and pharmaceutically acceptable carriers. Methods for treating ischemic disease include administering such pharmaceutical compositions to a person in need of such treatment.

Abstract: A demodulator capable of compensating for an offset voltage of a radio frequency (RF) signal, and a method of compensating for the offset voltage of the RF signal are provided. The demodulator includes an analog-to-digital conversion (ADC) unit for converting a first analog signal corresponding to a difference between the RF signal comprising the offset voltage and an analog reference signal into a first digital signal, and a compensation voltage generation unit for converting the first digital signal into an offset compensation voltage. The ADC unit converts a second analog signal corresponding to a difference between the RF signal comprising the offset voltage and the offset compensation voltage into a second digital signal. Accordingly, the offset voltage included in the RF signal is compensated for, and thus distortion and a signal-to-noise ratio (SNR) of the RF signal are reduced. This leads to an improvement of the reception sensitivity of an RF receiver.

Abstract: A pellicle frame, including aluminum, aluminum oxide, and a transition metal.

Abstract: Plasmids useful for treating ischemic disease, such as ischemic heart disease, are described. The plasmids express vascular endothelial growth factor (VEGF) under the control of a promoter (RTP801) that is up-regulated under hypoxic conditions. Pharmaceutical compositions for treating ischemic disease include mixtures of the hypoxia-regulated VEGF plasmids and pharmaceutically acceptable carriers. Methods for treating ischemic disease include administering such pharmaceutical compositions to a person in need of such treatment.

Abstract: Linear polyethylenimine was modified with sterols, such as cholesterol, in three different geometries: linear shaped (L), T-shaped (T), and a combined linear- and T-shaped (LT), to result in linear polyethylenimine-sterol conjugates. These conjugates were mixed with nucleic acids to form complexes for delivery of the nucleic acids into cells. Mammalian cells transfected with these complexes showed protein expression levels higher than linear polyethylenimine alone, and twice that of branched polyethylenimine, but without any significant loss in cell viability. Methods of making these compositions and methods of using them for gene delivery are also described.

Abstract: A demodulator capable of compensating for an offset voltage of a radio frequency (RF) signal, and a method of compensating for the offset voltage of the RF signal are provided. The demodulator includes an analog-to-digital conversion (ADC) unit for converting a first analog signal corresponding to a difference between the RF signal comprising the offset voltage and an analog reference signal into a first digital signal, and a compensation voltage generation unit for converting the first digital signal into an offset compensation voltage. The ADC unit converts a second analog signal corresponding to a difference between the RF signal comprising the offset voltage and the offset compensation voltage into a second digital signal. Accordingly, the offset voltage included in the RF signal is compensated for, and thus distortion and a signal-to-noise ratio (SNR) of the RF signal are reduced. This leads to an improvement of the reception sensitivity of an RF receiver.

Abstract: A carrier for delivering small interfering RNA (siRNA) into cells includes a cholesterol residue covalently bonded to oligoarginine. Mixing the siRNA with the carrier produces a complex-containing composition. Contacting a cell with the complex-containing composition results in delivery of the siRNA into the cell. Delivery of an siRNA targeted to vascular endothelial growth factor is a treatment for cancer. Methods of making the carrier and complex are also disclosed.

Abstract: A thermogelling, aliphatically modified polymer for use in drug delivery is described. Illustrative embodiments include poly(lactic-co-?-caprolactone)-poly(ethylene glycol)-poly(lactic-co-?-caprolactone) hexanoate and poly(lactic-co-?-caprolactone)-poly(ethylene glycol)-poly(lactic-co-?-caprolactone) laurate. Another illustrative embodiment includes a composition having a thermogelling amount of an aliphatically modified poly(lactic-co-?-caprolactone)-poly(ethylene glycol)-poly(lactic-co-?-caprolactone) and an effective amount of a drug. The thermogelling polymers are made by bonding an aliphatic group to poly(lactic-co-?-caprolactone)-poly(ethylene glycol)-poly(lactic-co-?-caprolactone). A method of use includes injecting a warm-blooded individual with a thermogelling amount of the aliphatically modified polymer and a drug.

Abstract: A carrier for delivering small interfering RNA (siRNA) into cells includes a cholesterol residue covalently bonded to oligoarginine. Mixing the siRNA with the carrier produces a complex-containing composition. Contacting a cell with the complex-containing composition results in delivery of the siRNA into the cell. Delivery of an siRNA targeted to vascular endothelial growth factor is a treatment for cancer. Methods of making the carrier and complex are also disclosed.

Abstract: An arginine-grafted bioreducible poly(disulfide amine) (“ABP”) as a reagent for efficient and nontoxic gene delivery is described. ABP forms positively charged nano-particles of less than 200 nm with siRNA. ABP is biodegraded under reducing conditions, such as in the cytoplasm. ABP exhibits much higher transfection efficiency than polyethyleneimine in mammalian cells and exhibits no cytotoxicity. ABP is an effective delivery vehicle for gene silencing with siRNA and may be used for treating cancer.

Abstract: Plasmids useful for treating ischemic disease, such as ischemic heart disease, are described. The plasmids express vascular endothelial growth factor (VEGF) under the control of a promoter (RTP801) that is up-regulated under hypoxic conditions. Pharmaceutical compositions for treating ischemic disease include mixtures of the hypoxia-regulated VEGF plasmids and pharmaceutically acceptable carriers. Methods for treating ischemic disease include administering such pharmaceutical compositions to a person in need of such treatment.

Abstract: An arginine-grafted bioreducible poly(disulfide amine) (“ABP”) as a reagent for efficient and nontoxic gene delivery is described. ABP forms positively charged nano-particles of less than 200 nm with plasmid DNA. ABP is biodegraded under reducing conditions, such as the cytoplasm. ABP exhibits much higher transfection efficiency than polyethyleneimine in mammalian cells and exhibits no cytotoxicity.

Abstract: Improved poly(amido ethylenimine) copolymers for gene delivery are disclosed. One illustrative embodiment includes polyethylene glycol (PEG) covalently bonded to a branched poly(triethyenetetramine/cystamine bisacrylamide) copolymer (poly(TETA/CBA)). The polyethylene glycol can be linear or branched. Another illustrative embodiment includes an RGD peptide covalently bonded to the poly(TETA/CBA)-PEG conjugate. Still another illustrative embodiment includes a method of using these compositions for transfecting a cell with a nucleic acid.

Abstract: Poly(disulfide amine)s, methods of making, and methods of use are described. Illustrative embodiments of the poly(disulfide amine)s include poly(CBA-DAE), poly(CBA-DAB), and poly(CBA-DAH). These compositions are made by Michael addition between N,N?-cystaminebisacrylamide and N-Boc-protected diamine monomers, followed by N-Boc deprotection. Complexes are formed by mixing the poly(disulfide amine)s with nucleic acid. Delivery of the nucleic acid into cells is carried out by contacting the cells with the nucleic acid/poly(disulfide amine) complexes.

Abstract: Disclosed herein is a nano- or micro-scale organic-inorganic composite device and a method for producing the same. The nano- or micro-scale organic-inorganic composite device includes a first electrode, a second electrode, and a photoactive layer formed of a fullerene-conducting polymer composite interposed between opposing surfaces of the first electrode and the second electrode, and a method of producing a nano- or micro-scale organic-inorganic composite device capable of mass production of the nano- or micro-scale organic-inorganic composite device, by producing an integrated structure of nano- or micro-scale organic-inorganic composite devices of a uniform size and quality using a porous template, where each device includes a first and second electrode, and a photoactive layer.

Abstract: Amphiphilic lipopeptide compositions for gene delivery are disclosed. An illustrative amphiphilic lipopeptide composition includes a human protamine 2 peptide conjugated to a hydrophobic moiety. Illustrative hydrophobic moieties include sterols, bile acids, and fatty acids. The amphiphilic lipopeptide composition is mixed with a nucleic acid such that the nucleic acid binds to the peptide portion of the lipopeptide. This mixture is placed in contact with mammalian cells to effect transfection of the cells with the nucleic acid. A method of making such amphiphilic lipopeptides is also described.

Abstract: An artery wall binding peptide (AWBP) based on the artery wall cell-binding domain of apolipoprotein B-100 was conjugated to a cationic backbone configured for forming a complex with a nucleic acid to produce a composition that enhances gene transfer to artery wall cells. An illustrative cationic backbone is poly(ethylene glycol)-grafted-poly(L-lysine) (PEG-g-PLL). Methods of making and using the composition for gene transfer are also described.